Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is an inpatient in a psychiatric hospital or an outpatient at a psychiatric setting at the time of the study entry.~* The patient is diagnosed with recurrent MDD according to DSM-IV-TR™ criteria (classification code 296.3x). The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has received prescribed treatment for a previous episode of depression.~* The patient has a MADRS total score ≥26.~* The reported duration of the current MDE is at least 3 months.~Exclusion Criteria:~* The patient has a score ≥70 on the DSST (number of correct symbols), or ≥42 on the RAVLT (learning) or ≥14 on the RAVLT (memory) at the Baseline Visit.~* The patient has any current Axis I disorder (DSM-IV-TR™ criteria) other than MDD, confirmed using the MINI.~* The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.~* The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).~* The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.~* The patient is diagnosed with reading disability (dyslexia).~* The patient is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide \<6 months prior to the Screening Visit.~* The patient has received electroconvulsive therapy \<6 months prior to the Screening Visit.~* The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the recommended dose.~* The patient has a history of moderate or severe head trauma (for example, loss of consciousness for more than 1 hour) or other neurological disorders or systemic medical diseases that are, in the opinion of the investigator, likely to affect central nervous system functioning.~* The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for \>5 years prior to the first drug dose.~* The patient has a clinically significant unstable illness, for example:~* cardiovascular disease~* seizure disorder or encephalopathy~* congestive heart failure~* cardiac hypertrophy~* arrhythmia~* bradycardia (pulse \<50 bpm)~* respiratory disease~* hepatic impairment or renal insufficiency~* metabolic disorder~* endocrinological disorder~* gastrointestinal disorder~* haematological disorder~* infectious disorder~* any clinically significant immunological condition~* dermatological disorder~* venereal disease~* The patient has, at the Screening Visit, an abnormal ECG that is, in the investigator's opinion, clinically significant.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~* The patient has previously been exposed to Vortioxetine.~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine 10 mg (Type: EXPERIMENTAL): None
- Vortioxetine 20 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).